These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30644585)

  • 1. Use of Cangrelor as a Bridge to Left Ventricular Assist Device Implantation in a Patient with a Recent Drug-Eluting Stent Who Developed Acute Tirofiban-Related Thrombocytopenia.
    Kabadi RA; Danelich IM; Entwistle JW; Marhefka GD; Reeves G; Boyle AJ; Qureshi AM
    Pharmacotherapy; 2019 Apr; 39(4):521-525. PubMed ID: 30644585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
    Van Tuyl JS; Newsome AS; Hollis IB
    Ann Pharmacother; 2019 Jul; 53(7):726-737. PubMed ID: 30646761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia.
    Gernhofer YK; Ross M; Khoche S; Pretorius V
    J Cardiothorac Surg; 2018 Apr; 13(1):30. PubMed ID: 29665860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
    Bowman S; Gass J; Weeks P
    Ann Pharmacother; 2019 Feb; 53(2):171-177. PubMed ID: 30132336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-term follow-up of tirofiban as alternative therapy for urgent surgery patients with an implanted coronary drug-eluting stent after ST-elevation myocardial infarction.
    Xia JG; Qu Y; Shen H; Liu XH
    Coron Artery Dis; 2013 Sep; 24(6):522-6. PubMed ID: 23900046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy.
    Calnan MW; Crawford AN
    J Pharm Pract; 2020 Apr; 33(2):231-235. PubMed ID: 30139291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 'bridging' antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel.
    Savonitto S; D'Urbano M; Caracciolo M; Barlocco F; Mariani G; Nichelatti M; Klugmann S; De Servi S
    Br J Anaesth; 2010 Mar; 104(3):285-91. PubMed ID: 20047898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention: JACC Review Topic of the Week.
    Sullivan AE; Nanna MG; Wang TY; Bhatt DL; Angiolillo DJ; Mehran R; Banerjee S; Cantrell S; Jones WS; Rymer JA; Washam JB; Rao SV; Ohman EM
    J Am Coll Cardiol; 2021 Oct; 78(15):1550-1563. PubMed ID: 34620413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cangrelor Bridging Within 6 Months of a Drug-Eluting Stent in a Patient for Emergency Cervical Spine Surgery: A Case Report.
    Hu TY; Peeters SM; Nagasawa DT; Kamdar NV; Brook RP; Sun J; Park S; Moreland NC; Cruz D; Macyszyn L; Press MC
    A A Pract; 2019 Jul; 13(2):69-73. PubMed ID: 30864953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cangrelor use prior to left ventricular assist device surgery: a case series.
    Washam JB; Yerokun B; Patel CB; Welsby IJ; Milano CA; DeVore AD
    J Thromb Thrombolysis; 2018 Aug; 46(2):131-133. PubMed ID: 29860606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cangrelor: a novel intravenous antiplatelet agent with a questionable future.
    Waite LH; Phan YL; Spinler SA
    Pharmacotherapy; 2014 Oct; 34(10):1061-76. PubMed ID: 25123696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions.
    Mauri L; Kereiakes DJ; Normand SL; Wiviott SD; Cohen DJ; Holmes DR; Bangalore S; Cutlip DE; Pencina M; Massaro JM
    Am Heart J; 2010 Dec; 160(6):1035-41, 1041.e1. PubMed ID: 21146655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial.
    Biondi-Zoccai GG; Valgimigli M; Sheiban I; Margheri M; Marzocchi A; Prati F; Vischi M; Lettieri C; Violini R; Sardella G; Stabile A; Clementi F; Romeo F; Colombo A; Sangiorgi G
    J Cardiovasc Med (Hagerstown); 2008 Sep; 9(9):957-62. PubMed ID: 18695440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Unusual Case of Drug-Induced Thrombocytopenia.
    Wang S; Sawalha K; Khan A
    J Investig Med High Impact Case Rep; 2020; 8():2324709620947891. PubMed ID: 32755257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Coronary stenting and surgery: perioperative management of antiplatelet therapy in patients undergoing surgery after coronary stent implantation].
    Rossini R; Bramucci E; Castiglioni B; De Servi S; Lettieri C; Lettino M; Musumeci G; Visconti LO; Piccaluga E; Savonitto S; Trabattoni D; Buffoli F; Angiolillo DJ; Bovenzi F; Cremonesi A; Scherillo M; Guagliumi G; ;
    G Ital Cardiol (Rome); 2012; 13(7-8):528-51. PubMed ID: 22781382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor for the treatment of arterial thrombosis: pharmacokinetics/pharmacodynamics and clinical data.
    Tamborini Permunian E; Riva N; Guasti L; Squizzato A
    Expert Opin Drug Metab Toxicol; 2015 Apr; 11(4):625-37. PubMed ID: 25728292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel use of cangrelor in pediatrics: A pilot cohort study demonstrating use in ventricular assist devices.
    Fahnhorst SE; Beasley G; Goldberg JF; Martinez HR; Ryan KA; Towbin JA; Boston U; Absi M
    Artif Organs; 2021 Jan; 45(1):38-45. PubMed ID: 33180355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.